STE · Intrinsic value
Is STERIS plc (STE) overvalued or undervalued?
As of Oct 19, 2026, TickerWorth's valuation lenses put STERIS plc (STE) at $96.04 – $295.05, too broad a range to say where the delayed market price of $222.66 sits in it, so we do not call it over- or undervalued. It is a model estimate, and every input behind it is sourced below.
Model by Miraaj Patel · generated from SEC filings and market data · Updated Oct 19, 2026 · How these pages are made
What is STE worth?
- Fair-value range
- $96.04 – $295.05
- Market price
- $222.66
- Gap to fair value
- —
- Verdict
- Too wide to call
Reverse DCF: Today's price implies revenue growth of 16.1% a year for 5 years; our model assumes 6.7% a year on average over the same horizon.
What is STE's TickerWorth Score?
Middle of the pack — real strengths and real weaknesses
Compared with Healthcare companies in US
Its strongest point: looks cheap on the numbers. Its weakest: trades above our estimate of what it's worth.
- Value · 61 of 100
Cheaper than 61% of Healthcare companies in US
- Price vs worth · 37 of 100
- Quality · 57 of 100
More profitable than 57% of Healthcare companies in US
- Financial health · 52 of 100
Financially stronger than 52% of Healthcare companies in US
- Growth · 48 of 100
Growing faster than 48% of Healthcare companies in US
- Momentum · 37 of 100
Outperformed 37% of Healthcare companies in US over the past year
Confidence: Medium confidence · Scored
Get the Undervalued Company of the Week.
Why STE gets a range, not one number
At a recent price of $222.66, STERIS plc (STE) sits inside a range too wide to call either way: our valuation lenses put the business somewhere between $96.04 and $295.05 per share. They disagree too widely for us to state a single fair value. We publish the range rather than a midpoint because a number that precise would claim more than the methods can support. This is an educational model, not a price target or a recommendation.
Read the full reasoning
The valuation discounts STERIS plc's projected free cash flows at a weighted-average cost of capital (WACC) of 9.2%, with a long-run terminal growth rate of 2.5%. About 74% of the enterprise value comes from the terminal value — the portion beyond the explicit forecast window — which is typical for a stable, cash-generative business and a reminder that small changes in the discount rate or terminal growth assumption swing the intrinsic value meaningfully.
Running the DCF in reverse — solving for the growth the current price already assumes — the market is implying roughly 16.1% annual revenue growth for STE. Our base case instead compounds to about 6.7% a year over the same forecast, so the market is pricing in materially faster growth than our base case. The reverse-DCF is a quick sanity check: it reframes 'is this stock cheap?' as 'do I believe the growth the price requires?' rather than arguing over a single point estimate of fair value.
Sensitivity matters more than any single number. Across a reasonable band of discount-rate assumptions, STE's modeled DCF value ranges from about $101.72 to $225.85 per share. If that range still sits below today's price, the market is optimistic relative to the model across the whole band; if it brackets the price, the stock is roughly fairly valued on our assumptions. Use the interactive slider to see exactly where your own cost-of-capital view lands.
How to read this page: the DCF fair value is what STERIS plc would be worth if its cash flows grow as modeled and are discounted at the stated WACC. The assumptions table shows every input and its source; the reverse-DCF shows what the market believes; the sensitivity band shows how fragile the answer is. None of this is investment advice — it is a transparent, auditable framework for forming your own view of STE's intrinsic value. Figures update as new filings and prices come in.
Every input behind STE's DCF
| Input | Value |
|---|---|
| Base-year revenueSTERIS plc FY2026 10-K (accession 0001628280-26-039136): us-gaap:Revenues, FY2026 full year. | $5,935,900,000 |
| Base EBIT marginSTERIS plc FY2026 10-K (accession 0001628280-26-039136): us-gaap:OperatingIncomeLoss 1,101,800,000 / revenue 5,935,900,000 = 18.56%, FY2026. | 18.6% |
| Forecast revenue growthESTIMATEAssumption — TickerWorth's 5-year explicit forecast | 9% → 8% → 7% → 5% → 4% |
| Risk-free rateLive feed — US 10-year Treasury yield (^TNX) | 5.2% |
| BetaLive feed — yfinance, 5-year monthly beta vs the S&P 500 (clamped to 0.4–2.5) | 0.91 |
| Terminal growthESTIMATEAssumption — TickerWorth house default 2.5%, held below WACC | 2.5% |
| Diluted sharesSTERIS plc FY2026 10-K (accession 0001628280-26-039136): WeightedAverageNumberOfDilutedSharesOutstanding = 98,700,000 shares, FY2026. | 99M |
| Market priceBackup price feed · as of 2026-10-19 13:19 UTC | $222.66 |
Change STE's assumptions
The discount-rate dial and the editable model
ProChange growth, margin and WACC yourself — Pro (7-day free trial, card required).
What does STERIS plc do?
What does it do?
STERIS plc provides infection prevention products and services in the United States, Ireland, and internationally. It operates through three segments: Healthcare, Applied Sterilization Technologies, and Life Sciences. It operates in the Medical Devices industry (Healthcare sector), headquartered in United States. The company employs roughly 17,937 people.
How does it make money?
The business turns $6.0B in annual revenue into profit. Out of every $100 of sales, about $19 is left as operating profit (operating margin of 19.2%), after a 44% gross margin on the products/services it sells. After all costs, taxes and interest, 13.3% of revenue becomes bottom-line net profit.
Is it financially healthy?
Financially it looks mixed: carries modest debt (0.3× equity), comfortably covers its short-term bills (1.9× current ratio), and is currently profitable.
Who at STE filed insider trades?
| Date | Insider | Relationship | What happened | Value | Filing |
|---|---|---|---|---|---|
| Burton Karen L | Sr. Vice Pres., CFO | Shares withheld (tax) | — | Form 4 for Burton Karen L (opens sec.gov in a new tab) | |
| Sohi Mohsen | Director | Option exercise | $349,921.34 | Form 4 for Sohi Mohsen (opens sec.gov in a new tab) | |
| Sohi Mohsen | Director | Open-market sale | $956,795.24 | Form 4 for Sohi Mohsen (opens sec.gov in a new tab) | |
| Sohi Mohsen | Director | Option exercise | $269,963.40 | Form 4 for Sohi Mohsen (opens sec.gov in a new tab) | |
| Sohi Mohsen | Director | Shares withheld (tax) | $389,995.10 | Form 4 for Sohi Mohsen (opens sec.gov in a new tab) | |
| Zangerle John Adam | Sr. VP, Gen Counsel, and Sec. | Open-market sale | $296,968.32 | Form 4 for Zangerle John Adam (opens sec.gov in a new tab) |
A disclosure, not a signal to trade. Source: SEC EDGAR (Form 4). Older filings and the 90-day buying-and-selling read are part of Pro. See plans
Common questions
What is STE's intrinsic value?
TickerWorth's valuation lenses put STERIS plc (STE) between $96.04 and $295.05 per share, versus a market price of $222.66. They disagree too widely for us to state a single fair value, so we publish the range.
Is STE overvalued or undervalued?
At $222.66 the price sits inside a range too wide to call either way. We don't call STE overvalued or undervalued from a range this wide. This is an educational estimate, not advice.
What discount rate is used for STE?
A WACC of 9.2% and a terminal growth rate of 2.5%.
Is STERIS stock undervalued?
TickerWorth's fair-value range for STERIS plc (STE) is $96.04 – $295.05 against a market price of $222.66. Too wide to call. We publish a range here, not one number, so we do not call it over- or undervalued. This is a model estimate, not investment advice.
STERIS (STE) DCF valuation and fair value
Our fair-value range for STERIS plc (STE) is $96.04 – $295.05, built on a 9.2% discount rate (WACC) and 2.5% terminal growth. It blends our discounted-cash-flow model with other valuation lenses. Every assumption is listed on this page with its source.
What growth is priced into STERIS stock?
Today's price implies revenue growth of 16.1% a year for 5 years; our model assumes 6.7% a year on average over the same horizon. This is a reverse DCF: it holds our cash-flow model's other inputs and solves for the revenue growth that makes the model equal today's price of $222.66. A model estimate, not investment advice.
STERIS (STE) insider trading
The most recent insider filing (SEC Form 4) for STERIS plc (STE): Burton Karen L, Sr. Vice Pres., CFO, shares withheld (tax) on 2026-10-01. The latest filings are listed on this page. A disclosure, not a signal to trade.
Other ways into the coverage
Not investment advice. TickerWorth Score is a model output.
Educational tool. Every output reflects the assumptions shown — not a prediction and not investment advice. TickerWorth is not a licensed investment adviser, and these figures are estimates from public filings and market data that can be wrong.